Receptor News and Research

RSS

Study shows CoronaVac to have high seroconversion rate after 40 days

Researchers from the Federal University of Paraná, Brazil, looked into the seroconversion rate after vaccination with the CoronaVac. Using immunoassays, they measured the immunoglobulins (IgG) for anti-nucleocapsid protein (anti-N) antibodies and anti-spike-1 (anti-S1) protein antibodies.

27 May 2021

Astodrimer sodium exhibits potent virucidal and antiviral activity against SARS-CoV-2 in vitro

Researchers from the US and Australia recently conducted some studies to assess the in vitro antiviral and virucidal (irreversible) activity of astodrimer sodium against SARS-CoV-2.

26 May 2021

Disproportionate number of SARS-CoV-2 breakthrough infections are caused by variants of concern

A study conducted by researchers in the United States has shown that among twenty patients with breakthrough infection following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – all of the infections were caused by variants of concerns.

26 May 2021

Intensity and duration of SARS-CoV-2 immunity may depend on ABO blood group

A team of scientists from Canada and Spain recently evaluated the durability of antigen-specific immune responses in COVID-19 recovered individuals. They have also identified potential host factors associated with robust and long-lasting anti-SARS-CoV-2 immunity.

26 May 2021

Could GRP78 be a therapeutic target against COVID-19?

A new study by a team of researchers at the Keck School of Medicine, University of Southern California, USA, reports a potentially important therapeutic target in the form of a molecule called GRP78 that promotes the entry and protein production by many viruses. The team's paper has been published in the Journal of Biological Chemistry.

26 May 2021

An exploratory study of T-cell and antibody responses after COVID-19 mRNA vaccination

Recent COVID-19 investigations have found that up to half of immunocompromised individuals struggle to produce antibodies after receiving their severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations.

26 May 2021

Immunologists decode T cell responses that occur during COVID-19 infection

An international team of researchers from the Institute for Research in Biomedicine, affiliated to the Università della Svizzera italiana, has deciphered, at single cell resolution, the T cell responses occurring during COVID-19 infection.

26 May 2021

Moderna's COVID vaccine proves effective against South African variant in primates

Researchers in the United States have demonstrated the efficacy of Moderna’s coronavirus disease 2019 (COVID-19) vaccine at protecting against the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in non-human primates.

26 May 2021

NFCR announces winners of 2021 Salisbury Award Competition

The National Foundation for Cancer Research (NFCR) announced winners of the 2021 Salisbury Award Competition for Entrepreneurial Translational Research, selected from among eight semi-finalists after pitch presentations in front of a judging committee consisting of prominent cancer research scientists, clinicians, early-stage investors and business leaders.

26 May 2021

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

A new study aims to identify antibody-based biomarkers associated with the humoral immune response that could be a standard CoP candidate for COVID-19. Further, standardization of research methods to measure these biomarkers has also been conducted.

25 May 2021

Study shows how neutralizing antibodies are produced after SARS-CoV-2 infection

A research group from Osaka University led by Professor Hisashi Arase and consisting of researchers from the Research Institute for Microbial Diseases, the Institute for Protein Research, the Immunology Frontier Research Center, the Center for Infectious Diseases, and the Graduate School of Medicine has discovered for the first time that both neutralizing antibodies that protect against infection as well as infection-enhancing antibodies that increase infectivity are produced after infection with SARS-CoV-2 by analyzing antibodies derived from COVID-19 patients.

25 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

The aim of this study investigates the impact of different types of vaccines on the anti-SARS-CoV-2 Immunoglobulin A (IgA) and Immunoglobulin G (IgG) antibody levels found in human milk.

25 May 2021

Superoxide produced in the inner ear cochlea causes major types of acquired hearing loss

Professor UEYAMA Takehiko (Biosignal Research Center, Kobe University) and the inner ear research group (Kyoto Prefectural University of Medicine) have identified the cell types in the inner ear cochlea responsible for the production of superoxide (Nox3-expressing cells).

25 May 2021

Discovery of novel SARS-related coronaviruses in bats

In a recent study published on the bioRxiv* server, Peng Zhou, Zheng-Li Shi and colleagues at the Wuhan Institute of Virology, with collaboration from scientists at the University of Chinese Academy of Sciences in China, have identified a new lineage of SARS-related coronaviruses that utilize bat angiotensin-converting enzyme 2 (ACE2) receptors for cell entry, which is the same receptor used by SARS-CoV-2 to infect host cells.

25 May 2021

Why COVID-19 patients have more pathogenic bacteria in their noses

Researchers compared the nasal microbiome of coronavirus disease 2019 (COVID-19) patients, healthy individuals, and healthcare workers. These studies indicated an increase in the pathogen Pseudomonas aeruginosa present in the nasal microbiome of COVID-19 patients, which may be responsible for other secondary infections.

24 May 2021

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Antibodies, Antibody, Assay, Coronavirus, Efficacy, Healthcare, Pandemic, Protein, Receptor, Research, Vaccine, Virus, Coronavirus Disease COVID-19,

24 May 2021

The potential therapeutic value of CDK6 inhibitors in critical COVID-19

While drug repurposing has been explored in the context of the current coronavirus disease 2019 (COVID-19) pandemic, the success of this strategy has been limited so far. A new study, released as a preprint on the medRxiv* server, describes a new method of identifying a promising hit among drugs already in use.

24 May 2021

Are COVID-19 medications safe in pregnancy?

Most medications being tested today in clinical trials for the treatment of coronavirus disease 2019 (COVID-19) have been repurposed from other indications. These are typically not tested in pregnant women. A new study, published in the journal PLOS ONE, summarizes what is known about the safety of these drugs in this group.

24 May 2021

Novel natural compounds may help treat COVID-19, study suggests

A new study in the journal Chemistry Europe reports two natural compounds identified by virtual screening and computational modeling as having great promise for the development of drugs against SARS-CoV-2.

24 May 2021

Receptor News and Research

Study shows CoronaVac to have high seroconversion rate after 40 days

Astodrimer sodium exhibits potent virucidal and antiviral activity against SARS-CoV-2 in vitro

Disproportionate number of SARS-CoV-2 breakthrough infections are caused by variants of concern

Intensity and duration of SARS-CoV-2 immunity may depend on ABO blood group

Could GRP78 be a therapeutic target against COVID-19?

An exploratory study of T-cell and antibody responses after COVID-19 mRNA vaccination

Immunologists decode T cell responses that occur during COVID-19 infection

Moderna's COVID vaccine proves effective against South African variant in primates

NFCR announces winners of 2021 Salisbury Award Competition

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

Study shows how neutralizing antibodies are produced after SARS-CoV-2 infection

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

Superoxide produced in the inner ear cochlea causes major types of acquired hearing loss

Discovery of novel SARS-related coronaviruses in bats

Why COVID-19 patients have more pathogenic bacteria in their noses

Researchers take steps to standardize correlates of protection against SARS-CoV-2

The potential therapeutic value of CDK6 inhibitors in critical COVID-19

Are COVID-19 medications safe in pregnancy?

Novel natural compounds may help treat COVID-19, study suggests

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News